Skip to content

Aura Biosciences, Inc. AURA Total costs & expenses

Total costs & expenses at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$114M+40.8%
CG Oncology logo
CG OncologyCGON
$67.47M+59.7%
The Oncology Institute, Inc. logo
The Oncology Institute, Inc.TOI
$153.95M+34.7%
Exelixis logo
ExelixisEXEL
$359.47M-2.5%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Operating income-$34.9M-20.1%
Net income-$33.7M-22.6%
EPS (diluted)-$0.50+9.1%

Balance sheet

See full
Cash & equivalents$84.8M+122%
Total debt$17.0M-7.9%
Total equity$107.2M-16.2%
Total assets$137.7M-11.4%

Cash flow

See full
Operating cash flow-$29.9M-28.0%
CapEx$102.0K-45.5%
Free cash flow-$30.0M-27.4%

Valuation

See full
Market cap$709.23M+89.4%
Enterprise value$641.43M+80.8%

Returns & leverage

See full
Return on equity-95.6%+222pp
Debt / equity0.2×0.0×
Current ratio7.1×-4.0×

Where this comes from

Reported directly by Aura Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingCostsAndExpenses.

The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aura Biosciences, Inc.'s total costs & expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aura Biosciences, Inc.'s total costs & expenses?
Aura Biosciences, Inc. (AURA) reported total costs & expenses of $34.87M in Q1 2026.
How has Aura Biosciences, Inc.'s total costs & expenses changed year-over-year?
Aura Biosciences, Inc.'s total costs & expenses increased by 20.1% year-over-year, from $29.04M to $34.87M.
What is the long-term trend for Aura Biosciences, Inc.'s total costs & expenses?
Over 4 years (2021 to 2025), Aura Biosciences, Inc.'s total costs & expenses has grown at a 33.7% compound annual growth rate (CAGR), from $35.25M to $112.79M.
What does total costs & expenses mean?
The aggregate sum of all operating expenses incurred by the company during a reporting period, including research and development, selling, general, and administrative costs. This metric represents the total resource consumption required to sustain business operations and advance clinical development pipelines. Monitoring this figure helps investors assess the company's overall burn rate and operational efficiency.